Quest Diagnostics Upgraded After Strong Q3, While Also Announcing New Test For Alzheimer's

Impact · against what's priced in

DGX is poised for upward revision based on the introduction of a new Alzheimer's test and a significant beat in Q3 EPS growth. While strong operational metrics are likely already reflected in the valuation, the expansion into high-demand specialty diagnostics provides a fresh catalyst for 2027 revenue.

DGX+0.40

No priced-in read yet